Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label, Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

NCT04023396 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT04023396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04023396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label, Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Lead sponsor
Abivax S.A.
Phase
Phase 2
Overall status
Completed
Start date
January 13, 2020
Completion date
February 23, 2023
Enrollment
217 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis